- We have filed multiple patents involving new chemical entities as treatments for chronic health disorders (i.e., addiction, mental health disorders, and cancer).
- Our clinical studies have evaluated the safety and efficacy of a novel medication to suppress the effects of cocaine in human subjects.
- We are currently investigating the first allosteric modulators of serotonin 5-HT2c receptors as treatments for addiction and mental health disorders. The first peptide nanofiber-based delivery platform has been pioneered for anti-addiction vaccines.
- The efficacy of new non-catechol dopamine D1 receptor agonists is being evaluated in the context of addiction and schizophrenia.